Baltimore is participating in the longest and largest Alzheimer?s clinical trial ever conducted, hoping to slow the growth of the disease that now afflicts 4.5 million Americans and is projected to affect 16 million by 2050.
Myriad Pharmaceuticals is conducting the trial, which will test a treatment called Flurizan, on 1,600 participants in 125 sites across the country.
People suffering from early Alzheimer’s can enroll in the trial to test the medication, expected to slow cognitive decline and help regain memory previously lost. Company officials say no treatment has been able to do this before.
“Most treatments only affect the symptoms, the use of existing capacity or brain cells,” said Dr. Marsden McGuire of Johns Hopkins Medical Institute.
The Phase Three trial is the last step in gaining approval from the Food and Drug Administration for the treatment.
Patients who participated in Phase Two of the trial have already improved and offer evidence that Flurizan may be a major breakthrough.
For information on the trial or on participating, call 888-459-4888 or visit www.myriad.com.
